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Abstract
TP53 aberrations reportedly predict favorable responses to decitabine (DAC) in acute myeloid leukemia (AML). We evaluated
clinical features and outcomes associated with chromosome 17p loss or TP53 gene mutations in older, unfit DAC-treated AML
patients in a phase II trial. Of 178 patients, 25 had loss of 17p inmetaphase cytogenetics; 24 of these had a complex (CK+) and 21
a monosomal karyotype (MK+). In analyses in all patients and restricted to CK+ and MK+ patients, 17p loss tended to associate
with higher rates of complete remission (CR), partial remission (PR), or antileukemic effect (ALE). Despite favorable response
rates, there was no significant OS difference between patients with or without loss of 17p in the entire cohort or in the CK+ and
MK+ cohort. TP53 mutations were identified in eight of 45 patients with material available. Five of the eight TP53-mutated
patients had 17p loss. TP53-mutated patients had similar rates of CR/PR/ALE but shorter OS than those with TP53 wild type
(P = 0.036). Moreover, patients with a subclone based on mutation data had shorter OS than those without (P = 0.05); only one
patient with TP53-mutated AML had a subclone. In conclusion, 17p loss conferred a favorable impact on response rates, even
among CK+ and MK+ patients that however could not be maintained. The effect of TP53 mutations appeared to be different;
however, patient numbers were low. Future research needs to further dissect the impact of the various TP53 aberrations in HMA-
based combination therapies. The limited duration of favorable responses to HMA treatment in adverse-risk genetics AML
should prompt physicians to advance allografting for eligible patients in a timely fashion.
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Introduction
The hypomethylating agents (HMA) decitabine (DAC) and
azacitidine (AZA) are a standard of care in AML and higher
risk MDS patients not eligible for intensive treatment. While
dynamic features, such as early platelet response [1], can be
used to estimate eventual treatment response, no pre-treatment
markers are in routine clinical use.
Several studies reported associations between outcomes of
patients with MDS or AML receiving HMAs and genetic
aberrations, DNA methylation, mRNA or microRNA expres-
sion, or other markers (e.g., HbF) [2–14]. Among these, we
described that patients with AML or MDS and a monosomal
karyotype (MK+) benefitted from DAC treatment, particular-
ly when multiple monosomies were present. [3, 9, 15] The
MK+ status is closely associated with the presence of a com-
plex karyotype (CK+) [15], and MK+ and CK+ are associated
withmutations in TP53 [16–19]. In turn, TP53mutations have
also been recently reported to be predictive for response in
patients with MDS or AML treated with DAC [11, 14].
Moreover, among patients with chromosome 17p aberrations,
those treated withAZA tended to have a better overall survival
(OS) than those treated with conventional care regimens [16].
The data were in part presented at the 23rd Annual Congress of the
European Hematology Association, Stockholm, Sweden, June 14–17,
2018.
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Here, we evaluated the genetic and clinical characteristics
associated with loss of chromosome 17p or gene mutations
affecting TP53 in older, unfit AML patients treated with DAC
within a phase II trial.
Patients and methods
Patients and treatment
Patients were enrolled onto the phase II trial 00331
(German Clinical Trials Registry DRKS00000069), the
results of which have been previously reported [3].
Briefly, 227 patients with AML (by French-American-
British classification), who were ineligible for intensive
chemotherapy, were treated with DAC (15 mg/m2 every
8 h for 3 consecutive days, total dose of 135 mg/m2, every
6 weeks). In case of an antileukemic effect (ALE) or stable
disease (SD) after course 1, administration of the second
course of DAC was followed by all-trans retinoic acid
(ATRA; 45 mg/m2/day) for 28 days. Patients with com-
plete remission (CR), partial remission (PR), or ALE after
completion of 4 courses were eligible to receive mainte-
nance treatment with DAC at 20 mg/m2/day (for 3 consec-
utive days, every 6–8 weeks). Bone marrow aspirates were
performed after courses 1, 2, and 4. Morphology was cen-
trally reviewed. The following response definitions were ap-
plied [3]: CR: BM blasts < 5%, platelets > 100 × 109/L, white
blood cells (WBC) > 1.5 × 109/L, and no extramedullary leuke-
mia. PR: BM blasts 5–25%, platelets > 100 × 109/L, WBC >
1.5 × 109/L, and no clinical or imaging evidence of leukemia; or
BM blasts < 5%, platelet count < 100 × 109/L, WBC <1.5 × 109/
L. ALE: > 25% reduction of BM blasts relative to the initial blast
percentage but not enough to fulfill the criteria for a PR. The study
was approved by the institutional review boards of each center.
All patients had givenwritten informed consent for collection and
use of data and specimens. All procedures followed were in ac-
cordance with the ethical standards of the responsible committee
and with the Helsinki Declaration.
Cytogenetics and gene mutations
Metaphase karyotypes were centrally reviewed and CK+ and
MK+ status assigned as previously described [3, 15]. MK+ re-
quired presence of a single autosomal monosomy and a structural
aberration, or two or more autosomal monosomies [15]. Loss of
17p was evaluated based on the available karyotype data.
Data on mutations inDNMT3A and NPM1 and FLT3-internal
tandem duplications (ITD) had been previously reported [17]. For
the present study, bone marrow (n= 27) and peripheral blood
(n = 18) samples of 45 patients were analyzed using the
Illumina TruSight Myeloid Sequencing Panel (covering 54 genes
relevant in myeloid neoplasms) for library preparation and an
Illumina MiSeq device for sequencing. Variants located in in-
trons, synonymous variants, and known single nucleotide poly-
morphisms were excluded. Variants had to feature a variant allele
frequency (VAF) of > 5% for missense variants, or had to be hot
spot mutations or mutations known to be present in the given
patient, or had to be large insertions or deletions. Variants had
to be covered by > 100 reads, and the variant had to be observed
in > 10 reads. Four of six amplicons covering CEBPA only gave
insufficient reads for analysis, thus CEBPA mutations may be
underestimated. The genetic data were used to derive the clonal
architecture (detailed in the supplemental).
Statistical analyses
CR, PR, ALE, SD, progressive disease (PD), early death
(ED). and OS (time from start of treatment to death) were
defined as previously described. [3] All patients who had re-
ceived at least one dose of DACwere included in the analysis.
The Fisher’s exact and Wilcoxon rank sum tests were used to
compare categorical or continuous variables, respectively.
Estimated probabilities of OS were calculated using the
Kaplan-Meier method. Group differences were assessed using
the log-rank test and univariate Cox proportional hazards
models.
Results
Association of loss of 17p with pre-treatment charac-
teristics and outcomes
As previously published, [3] cytogenetic data were available
for 177 patients; 120 patients had clonal cytogenetic aberra-
tions. Of these, 25 patients were identified to have loss of 17p;
24 of them were CK+, and 21 were MK+ (Table 1).
We evaluated the outcome of patients with loss of 17p com-
pared with those without in the entire cohort of patients with
cytogenetic data and in the subgroups of CK+ or MK+ patients
(Table 2, Fig. 1a–c). Patients with loss of 17p overall tended to
have favorable response rates in comparisonwith patients without
loss of 17p (CR/PR/ALE vs SD/PD/ED, P= 0.08). This was also
true when analyses were conducted only among patients with
CK+ (P= 0.01) or MK+ (P= 0.05). However, despite these fa-
vorable response rates and although the median OS was longer
for patients with loss of 17p especially in the CK+ and MK+
cohort, there was no significant difference in the OS between
patients with or without loss of 17p in the entire cohort or in the
CK+ andMK+ cohort, as the OS curves crossed shortly after the
6-month mark.
Of the patients with cytogenetic data, 77 had received ATRA
in addition to DAC, 49 of them over the entire planned period of
4 weeks during course 2. Only six of the 49 patients had a loss of
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17p. The low number of patients and the bias regarding the se-
lection of patients receiving ATRA precluded further analyses.
Gene mutation profiles and clonal architecture
Among the 45 patients with samples available for sequencing,
the median age was 75 years (range, 63–83), and 27 (60%)
had AML secondary to MDS.We identified a median of three
mutations (range, 0–9) or three mutated genes (range, 0–6) per
patient, respectively; nine patients had more than one muta-
tion in a given gene, and in three (7%) patients, no mutations
were identified (Fig. 2, Supplemental Table S2). Most fre-
quently mutated genes were ASXL1 (29% of patients),
RUNX1 (24%), SRSF2 (24%), IDH1 (9%) or IDH2 (13%),
TET2 (18%), and TP53 (18%).
Based on the sequencing and cytogenetic data, the clonal
architecture could be derived in 33 patients (Fig. 2,
Supplemental Table S2). In nine patients, one or more minor
subclones (defined through mutations present in a cell fraction
that was > 20% smaller than the major clone) were present;
while in the remaining 24 patients, no subclones in addition to
the major clone could be identified.
Genetic and clonal features of the TP53 mutations
The TP53mutations were located in exons 4 (n = 2), 5 (n = 3),
7 (n = 3), and 10 (n = 1) (Supplemental Table S2); one patient
had twomutations. Three TP53mutations were truncating, the
remaining were missense substitutions.
Five patients with a TP53 mutation also had a cytogenetic
loss of 17p. In one of these patients, the VAF of the TP53
mutation indicated the loss of the TP53 wild-type allele (i.e.,
VAF > 60%); one other patient with loss of 17p had two mu-
tations in TP53. One patient with a TP53 mutation with a
Table 1 Clinical characteristics of AML patients with or without loss of 17p
Loss of 17p (n = 25) No loss of 17p (n = 152) P value
Age, years median (range) 71 (61–82) 72 (56–86) 0.49
Sex, n (%) female 11 (44%) 51 (34%) 0.37
Prior MDS, n (%) yes 10 (40%) 88 (58%) 0.13
WBC, × 109/L median (range) 2.7 (0.5–83.3) 5.8 (0.6–86.2) 0.05
Platelets, × 109/L median (range) 56 (12–207) 36 (3–894) 0.08
Hemoglobin, g/dl median (range) 8.6 (5.8–11.3) 9.0 (1.4–13.0) 0.44
LDH, U/L median (range) 383 (180–4081) 279 (121–2261) 0.06
PB blasts, % median (range) 11 (0–63) 15 (0–96) 0.53
BM blasts, % median (range) 61 (10–100) 50 (18–100) 0.21
CK status, n (%) CK+ CK− 24 (96%) 1 (4%) 28 (18%) 124 (82%) < 0.001
MK status, n (%) MK+ MK− 21 (84%) 4 (16%) 17 (11%) 135 (89%) < 0.001
DAC courses, n median (range) 2 (1–12) 2 (1–23) 0.66
MDSmyelodysplastic syndromes, nd not determined, FAB French-American-British classification,WBCwhite blood cells, LDH lactate dehydrogenase,
PB peripheral blood, BM bone marrow, CK complex karyotype, MK monosomal karyotype, DAC decitabine
Table 2 Comparison of response rates and overall survival in various genetic groups
CR PR ALE SD PD ED CR/PR/ALE n (%) CR/PR/ALE vs SD/PD/ED P value MedianOS (months) P value
Loss of 17p (n = 25) 6 4 8 3 1 3 18 (72%) – 6.0 –
No loss of 17p (n = 152)* 20 20 38 38 17 16 78 (52%) 0.08 5.5 0.11
CK+/loss of 17p (n = 24) 6 4 7 3 1 3 17 (71%) – 6.0
CK+/no loss of 17p (n = 28) 2 4 4 7 6 5 10 (36%) 0.01 3.9 0.64
MK+/loss of 17p (n = 21) 6 4 6 2 1 2 16 (76%) – 6.0 –
MK+/no loss of 17p (n = 17) 2 2 3 6 3 1 7 (41%) 0.05 3.8 0.50
TP53 mut (n = 8) 0 1 2 1 1 3 3 (38%) – 1.8 –
TP53 wt** (n = 37) 0 6 12 10 4 4 18 (50%) 0.70 4.4 0.036
CR complete remission, PR partial remission, ALE antileukemic effect, SD stable disease, PD progressive disease, ED early death, OS overall survival,
CK complex karyotype, MK monosomal karyotype
*In 3 patients, best response was not evaluable
**In 1 patient, best response was not evaluable
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VAF > 60% had no chromosome 17 aberration by metaphase
karyotyping. TP53-mutated AMLs more often were CK+
(P < 0.001), MK+ (P = 0.02), or harbored a loss of 17p
(P < 0.001) than TP53 wild-type AML (Table 3).
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The TP53 mutations were all present in the major AML
clone of the respective patient. Only one patient (13%) with a
TP53-mutated AML had a minor subclone, while 8 (32%) of
the patients with TP53 wild-type AML did. Patients with a
TP53 mutation harbored a median of only one additional mu-
tation (range, 0–4).
Association of TP53 mutations with clinical features
and outcome
Compared with TP53wild type, patients with TP53mutations
were younger (P = 0.01; median, 71 vs 77 years); AML with
TP53mutation tended to more often develop from antecedent
MDS (P = 0.12) (Table 3).
In the outcome comparisons between AML patients
with mutated or wild-type TP53, there were no differences
in the response rates, but patients with TP53 mutations had
a shorter OS than those with wild-type TP53 (P = 0.036)
(Table 2, Fig. 1d).
Twenty-four of the patients with sequenced samples had
received ATRA. Of these, only three harbored a TP53 muta-
tion, which precluded outcome analyses.
Association between other mutations and outcome
Other markers previously reported to be associated with out-
comes in DAC-treated patients are mutations in SRSF2, [11]
DNMT3A, [2, 17] TET2, [7] IDH1, or IDH2. [8, 14]We found
no differences in response rates or OS between patients with
or without mutations in these genes or in at least one RNA
splicing gene (data not shown). Moreover, there were no dif-
ferences in response rates and OS between patients with ≤ 3
mutated genes and those with > 3 mutated genes
(Supplemental Table S3).
However, the presence of subclones was associated with a
shorter OS in comparison with their absence (P= 0.05) (Fig. 1e,
Supplemental Table S3). Only one of the 9 patients with a minor
subclone also harbored a TP53 mutation. Since both a TP53
mutation and presence of a minor subclone were associated with
shorter OS, we combined patients with at least one of these fea-
tures into one group and compared them with the remaining.
Compared with patients with TP53 wild type and absence of a
Fig. 2 Genetics in AML patients analyzed via panel sequencing. Each
line represents a patient, and each column contains the genetic
information as indicated. Patients are ordered by the presence of a TP53
mutation and/or loss of 17p, and then by the mutation status of the re-
maining genes according to their order in the columns. In case of mutated
genes, the variant allele frequency (VAF) is indicated: VAF > 25%, red;
11–25%, orange; ≤ 10%, light orange. If a gene harbored more than one
mutation in a patient, the VAF of each mutation is provided. Wild-type
sequence is color-coded in green. Rarely mutated genes are summarized
in a column called other and the gene name is specified in the cell. For
mutations in FLT3, the localization is specified: ITD, internal tandem
duplication in the juxtamembrane (JM) domain; JM, point mutations in
the JM domain; TKD, point mutations in tyrosine kinase domain. The
presence of a minor subclone is indicated in red, its absence in green.
Missing data are color-coded in gray
Fig. 1 Overall survival according to a-c the presence or absence of loss of
17p among a all patients with cytogenetic information, b patients with
CK+ and c patients with MK+, and overall survival according to d the
presence or absence of a TP53 mutation among all patients with samples
subjected to panel sequencing (corresponding COX model: HR 2.31,
95% CI 1.03–5.16, P = 0.041), e the presence or absence of minor
subclones among patients with available data (corresponding COX
model: HR 2.29, 95% CI 0.98–5.39, P = 0.056), and f the presence of a
TP53 mutation or a minor subclone or absence of both among patients
with available data (corresponding COX model: HR 2.63, 95% CI 1.20–
5.79, P = 0.016)
R
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minor subclone, those with a TP53mutation or a minor subclone
expectedly had shorter OS (P= 0.01); no differences in the re-
sponse rates were observed (Fig. 1f, Supplemental Table S3).
Discussion
HMAs have become a standard of care in AML patients not
eligible for intensive chemotherapy. Chromosomal or molec-
ular aberrations of TP53 are likely central in the investigation
of markers and biological pathways associated with the re-
sponse to HMAs [5, 7, 10–12, 14, 16, 18, 19]. Thus, we
sought to investigate the impact of loss of 17p and TP53
mutations in our phase II trial 00331 in which older unfit
AML patients were treated with 3-day DAC.
We observed that patients with a loss of 17p tended to have
higher rates for CR/PR/ALE both in analyses including all
patients and in those restricted to CK+ and MK+ patients.
Among CK+ and MK+ patients, patients with loss of 17p also
had longer median OS, but this favorable course could not be
maintained over time. Patients with TP53-mutated AML had
similar rates of CR/PR/ALE but shorter OS than those with
wild-type TP53 (P = 0.036).
Published data on the impact of chromosome 17p aberra-
tions on response to HMA treatment are scarce. Nazha et al.
[20] observed no difference in the response rates according to
chromosome 17 aberrations in MK+ and CK+ patients treated
with HMAs. In an explorative retrospective analysis of the
AZA-AML-001 study, patients with chromosome 17p aberra-
tions had a strong trend for better OS when treated with AZA
as compared with conventional care regimens (mainly low-
dose cytarabine) [16].
The impact of TP53mutations (or expression) on outcomes
in HMA-treated MDS or AML patients has been assessed in
several studies and yielded heterogeneous results. [7, 10–12,
14, 16, 19]Welch et al. [11] observed in patients with AML or
MDS that achievement of CR was more frequent in patients
with a TP53mutation. Moreover, in contrast to the poor OS of
TP53-mutated AML patients after standard induction, there
was no OS difference according to TP53 mutation status in
patients receiving DAC. In the aforementioned analysis of the
AZA-AML-001 study, patients with TP53-mutated AML had
strong trends for improved OS when treated with AZA com-
pared with alternative therapies [16]. However, in studies
among MDS patients treated with DAC or AZA, TP53 muta-
tions had no impact on response rates but were associated with
shorter response duration and/or OS [7, 10]. In another report
on patients withMDS (mostly with blast excess) who received
DAC, most patients with TP53 mutations achieved a CR, but
they still had inferior OS [14].
In MDS, mono-allelic TP53 mutations associate with more
favorable disease features (including less frequent complex kar-
yotype and better OS) than multi-hit TP53 mutations [21]. The
role of TP53 mutations under consideration of their allelic state
remains to be established. Welch et al. [11] described that two-
thirds of the patients with TP53 mutations potentially had both
alleles affected. In our study, 5 patients fulfilled the criteria of a
TP53 multi-hit mutation (i.e., multiple gene mutations or gene
mutation plus genomic loss) according to Bernard et al. [21].
The low patient numbers precluded meaningful outcome analy-
ses. Hopefully, future studies will be able to decipher the impact
of the allelic state of TP53 and its impact in response to DAC.
Considering our results and those reported by others, it cur-
rently remains elusive whether the TP53 aberrations or rather
associated genetic features may confer sensitivity to HMAs. As
observed in the present study, TP53 mutations and chromosome
17p aberrations coincide with CK+ and MK+ [22–26]; and for
trial 00331, which was subject to the present study, we previously
reported that MK+ patients had higher response rates and similar
OS compared with MK− patients [3]. Similar results have been
reported by Wierzbowska et al. [27] from a post hoc analysis of
the phase 3 DACO-016 trial in AML and by our group from the
phase 3 EORTC trial 06011 in MDS [9, 28]. In the study by
Welch et al. [11], almost all patients with TP53 mutations had
unfavorable cytogenetics, and achieving a CRwas more frequent
in patients with unfavorable than those with intermediate or fa-
vorable cytogenetics. In the study by Chang et al. [14], almost all
TP53-mutated patients who achieved a CR were CK+ or had
monosomies.
Welch et al. [11] suggested that a variable response of TP53-
mutated AML to DAC may be due to the presence of TP53
mutations in subclones instead of the major clone. We observed
no superior response to DAC, although TP53mutations were all
present in the major clone, and despite other features supporting
their disease-driving effect, i.e. TP53-mutated AML only rarely
harbored a minor subclone and had a low number of additional
mutations [7].However,we did observe that patientswith aminor
subclone had shorter OS than those without, although only one of
the nine patients with a minor subclone also harbored a TP53
mutation.
The heterogeneity in the reports on associations between TP53
aberrations and response toHMAsmay be due toweaknesses that
are variably shared by the studies, including the present study.
First, analyses are often based on relatively small patient numbers
[11, 14, 16]. Second, if provided, the information on 17p loss
normally stems from conventional cytogenetics, although the
(presumably lost) TP53 allele may be present in unidentified
chromosome material. [16, 29] Third, cohorts variably comprise
MDS or AML patients or both, although DAC may have higher
efficacy in patients with higher blast counts [30, 31]. Fourth, there
is the heterogeneity in treatment. In several studies, patients treat-
ed with DAC or AZA were combined into one group [7, 10], or
patients were included who received DAC combined with anoth-
er agent [2, 3, 7, 10]. Moreover, DAC was administered accord-
ing to different protocols. The majority of the patients received
DAC according to the 5-day protocol (total of 100 mg/m2 over
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5 days) [10, 14]. In the study byWelch et al. [11], the majority of
patients received DAC according to the 10-day protocol (total
200 mg/m2 over 10 days). Patients in our present study received
DAC according to the 3-day protocol (total of 135 mg/m2 over
3 days; every 6 weeks), in part of the patients followed by a
reduced dosage maintenance phase. Moreover, in the present
study, the patientswith loss of 17p orTP53mutation had received
only a median of 2 (range, 1–12) or 1 (range, 1–6) DAC courses,
while several courses are normally required to achieve best
response.
While the clinical observation of the (counter-intuitive) re-
sponse to HMAs in adverse genetics AML/MDS is more and
more accepted within the clinical community, the underlying
mechanism of the interaction between hypomethylating activity
and these genotypes is still unresolved.Monosomal chromosomal
regions may preferentially attract epigenetic silencing [32, 33],
providing a particularly sensitive target to DNMT inhibition.
Despite the present lack of a conclusive model of this interaction,
clinicians need to be aware that the responses, while surprisingly
frequent, are often short-lived. Hence, they can also be quite
deceptive, by raising unfounded optimism regarding their dura-
tion. Thus, patients with adverse genetics who are eligible for
allografting should transition to this curative treatment in a timely
manner, i.e., before HMA resistance sets in.
Table 3 Characteristics of
patients with samples analyzed
via panel sequencing according to
the TP53 mutation status
TP53 mut (n = 8) TP53 wt (n = 37) P value
Age, years median (range) 71 (66–77) 77 (63–83) 0.01
Sex, n (%) female 2 (25%) 16 (43%) 0.45










4.05 (0.90–11.30) 4.80 (0.50–35.70) 0.72
Platelets, × 109/L
median (range)
34 (3–137) 42 (9–324) 0.61
Hemoglobin, g/dl
median (range)
8.2 (6.5–9.3) 8.9 (5.0–10.8) 0.19
LDH, U/L
median (range)
320 (203–894) 281 (134–2216) 0.19
PB blasts, %
median (range)
28 (0–63) 20 (0–90) 0.57
BM blasts, %
median (range)
47 (10–81) 69 (21–95) 0.17
CK status, n (%) < 0.001
CK+ 8 (100%) 4 (15%)
CK− 0 22 (85%)
nd 0 11
MK status, n (%) 0.02
MK+ 4 (50%) 2 (8%)
MK− 4 (50%) 24 (92%)
nd 0 12
Loss of 17p status, n (%) < 0.001
Loss of 17p 5 (63%) 0




1 (1–6) 2 (1–11) 0.22
MDS myelodysplastic syndromes, nd not determined, FAB French-American-British classification, WBC white
blood cells, LDH lactate dehydrogenase, PB peripheral blood, BM bone marrow, CK complex karyotype, MK
monosomal karyotype, DAC decitabine
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In summary, within the specifications of the patient cohort
studied, loss of 17p was associated with trends for higher
DAC response rates, both within the entire cohort and among
patients with CK+ or MK+ AML. Patients with a TP53 mu-
tation achieved similar response rates as patients with wild-
type TP53, but had a shorter OS. Our data further support the
potential applicability of TP53 aberrations as predictor for
HMA treatment, and emphasize a possible role for subclonal
mutations in this regard. Isolated TP53 mutation analyses ap-
parently are not sufficient for prediction of HMA response.
Cytogenetic analysis remains standard and allows for evalua-
tion of MK+ status and 17p loss. The landscape of HMA-
based therapy is changing, and favorable responses in adverse
genetics patients are also observed when these drugs are com-
bined with the BCL-2 inhibitor venetoclax [34] or all-trans
retinoic acid [35]. Hence, the impact of the different types of
adverse cytogenetics and TP53 alterations (e.g., cytogenetic
and molecular genetic mono- or bi-allelic loss) on outcome
after HMA combination studies will be of great interest.
Acknowledgments We wish to thank Gabriele Greve, Ruhtraut Ziegler,
Tobias Ma, Philipp Sander, Christoph Niemöller, and Dennis Zimmer for
help during the project.
Authors’ contributions HB: Concept design; data acquisition, analyses,
and interpretation; manuscript preparation; critical revision and final ap-
proval of the manuscript. DP: Data acquisition, analyses, and interpreta-
tion; critical revision and final approval of the manuscript. GI: Data ac-
quisition, analyses, and interpretation; critical revision and final approval
of the manuscript. MP: Data analyses and interpretation; critical revision
and final approval of the manuscript. JW: Data analyses and interpreta-
tion; critical revision and final approval of the manuscript. BHR:
Treatment of patients and specimen acquisition; critical revision and final
approval of the manuscript. LB: Data acquisition, analyses, and interpre-
tation; critical revision and final approval of the manuscript. BH:
Treatment of patients and specimen acquisition; data acquisition, analy-
ses, and interpretation; critical revision and final approval of the manu-
script. UG: Treatment of patients and specimen acquisition; critical revi-
sion and final approval of the manuscript. AK: Treatment of patients and
specimen acquisition; critical revision and final approval of the manu-
script. UP: Treatment of patients and specimen acquisition; critical revi-
sion and final approval of the manuscript. KD: Treatment of patients and
specimen acquisition; data acquisition, analyses, and interpretation; crit-
ical revision and final approval of the manuscript. AG: Treatment of
patients and specimen acquisition; critical revision and final approval of
themanuscript. AH: Data acquisition, analyses, and interpretation; critical
revision and final approval of the manuscript. PWW: Treatment of pa-
tients and specimen acquisition; critical revision and final approval of the
manuscript. HD: Treatment of patients and specimen acquisition; critical
revision and final approval of the manuscript. JD: Concept design; data
interpretation; critical revision and final approval of the manuscript. ML:
Concept design; treatment of patients and specimen acquisition; data
interpretation; manuscript preparation; critical revision and final approval
of the manuscript.
Funding information OpenAccess funding provided by ProjektDEAL. The
research was supported by the Translational Research Training inHematology
(TRTH) of the European Hematology Association (EHA) and American
Society of Hematology (ASH) (to HB), the Berta Ottenstein Fellowship pro-
gram of the University of Freiburg (to JW), the German Research Foundation
[DFG; SPP 1463ML429/8-1 (toML); CRC992MEDEPC04 (toML); FOR
2674 A05 BE 6461/1-1 (to HB), LU 429/16-1 (to ML); FOR 2674 A02 (to
HD, KD, LB)], the Böhringer Ingelheim Stiftung [Exploration Grant (to HB)],
and the German Cancer Aid [111210 (to HB)].
Compliance with ethical standards
The study was approved by the institutional review boards of each center.
All patients had given written informed consent for collection and use of
data and specimens. All procedures followed were in accordance with the
ethical standards of the responsible committee and with the Helsinki
Declaration.
Conflict of interest The authors declare that they have no competing
interests.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Jung HA, Maeng CH, Kim M, Kim S, Jung CW, Jang JH (2015)
Platelet response during the second cycle of decitabine treatment
predicts response and survival for myelodysplastic syndrome pa-
tients. Oncotarget 6:16653–16662. https://doi.org/10.18632/
oncotarget.3914
2. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB,
Bloomfield CD, BlumW,Marcucci G (2012) DNMT3Amutations
and response to the hypomethylating agent decitabine in acute my-
eloid leukemia. Leukemia 26:1106–1107. https://doi.org/10.1038/
leu.2011.342
3. Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing
U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O,
Brugger W, Heil G, Hackanson B, Deschler B, Döhner K,
Hagemeijer A, Wijermans PW, Döhner H (2012) A multicenter
phase II trial of decitabine as first-line treatment for older patients
with acute myeloid leukemia judged unfit for induction chemother-
apy. Haematologica 97:393–401. https://doi.org/10.3324/
haematol.2011.048231
4. Wang H, Fan R, Wang X-Q, Wu DP, Lin GW, Xu Y, Li WY
(2013) Methylation of Wnt antagonist genes: a useful prognostic
marker for myelodysplastic syndrome. Ann Hematol 92:199–209.
https://doi.org/10.1007/s00277-012-1595-y
5. Yi L, Sun Y, Levine A (2014) Selected drugs that inhibit DNA
methylation can preferentially kill p53 deficient cells. Oncotarget
5:8924–8936. https://doi.org/10.18632/oncotarget.2441
6. Yun H, Damm F, Yap D, Schwarzer A, Chaturvedi A, Jyotsana N,
Lübbert M, Bullinger L, Döhner K, Geffers R, Aparicio S,
Humphries RK, Ganser A, Heuser M (2014) Impact of MLL5 ex-
pression on decitabine efficacy and DNA methylation in acute my-
eloid leukemia. Haematologica 99:1456–1464. https://doi.org/10.
3324/haematol.2013.101386
1558 Ann Hematol (2020) 99:1551–1560
7. Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A,
Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-
Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma
DP, Ebert BL (2014) TET2 mutations predict response to
hypomethylating agents in myelodysplastic syndrome patients. Blood
124:2705–2712. https://doi.org/10.1182/blood-2014-06-582809
8. Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus
RG,WetzlerM,WangES, EtemadiA,Griffiths EA (2015) Presence of
isocitrate dehydrogenase mutations may predict clinical response to
hypomethylating agents in patients with acute myeloid leukemia. Am
J Hematol 90:E77–E79. https://doi.org/10.1002/ajh.23965
9. Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U,
Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR,
Muus P, Pflüger K-H, Schaefer H-E, Bogatyreva L, Aul C, de
Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga
E, Baron F, Marie J-P, Wijermans PW (2015) Decitabine improves
progression-free survival in older high-riskMDS patients with mul-
tiple autosomal monosomies: results of a subgroup analysis of the
randomized phase III study 06011 of the EORTC Leukemia
Cooperative Group and German MDS Study Group. Ann
Hematol 95:191–199. https://doi.org/10.1007/s00277-015-2547-0
10. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E,
Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J,
Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G (2016) Clinical
implications of TP53 mutations in myelodysplastic syndromes treated
with hypomethylating agents. Oncotarget 7:14172–14187. https://doi.
org/10.18632/oncotarget.7290
11. Welch JS, Petti AA, Miller CA, Fronick CC, O’LaughlinM, Fulton
RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS,
Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I,
Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST,
Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE,
Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel
RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC,
DiPersio JF, Ley TJ (2016) TP53and decitabine in acute myeloid
leukemia and myelodysplastic syndromes. N Engl J Med 375:
2023–2036. https://doi.org/10.1056/NEJMoa1605949
12. van der Helm LH, Berger G, Diepstra A, Huls G, Vellenga E (2017)
Overexpression of TP53 is associated with poor survival, but not
with reduced response to hypomethylating agents in older patients
with acute myeloid leukaemia. Br J Haematol 178:810–812. https://
doi.org/10.1111/bjh.14166
13. Lübbert M, Ihorst G, Sander PN, Bogatyreva L, Becker H,
Wijermans PW, Suciu S, Bissé E, Claus R (2017) Elevated fetal
haemoglobin is a predictor of better outcome in MDS/AML pa-
tients receiving 5-aza-2′-deoxycytidine (decitabine). Br J
Haematol 176:609–617. https://doi.org/10.1111/bjh.14463
14. Chang C-K, Zhao Y-S, Xu F, Guo J, Zhang Z, He Q, Wu D, Wu
LY, Su JY, Song LX, Xiao C, Li X (2016) TP53mutations predict
decitabine-induced complete responses in patients with
myelodysplastic syndromes. Br J Haematol 176:600–608. https://
doi.org/10.1111/bjh.14455
15. Breems DA, Van Putten WLJ, De Greef GE, Van Zelderen-Bhola
SL, Gerssen-Schoorl KBJ, Mellink CHM, Nieuwint A, Jotterand
M, Hagemeijer A, Beverloo HB, Bob Löwenberg (2008)
Monosomal karyotype in acute myeloid leukemia: a better
Indicator of poor prognosis than a complex karyotype. JCO 26:
4791–4797. https://doi.org/10.1200/JCO.2008.16.0259
16. Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone
RM, Bernal del Castillo T, Al-Ali HK, Santini V, Vyas P, Beach
CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L,
Dombret H (2018) Cytogenetics and gene mutations influence sur-
vival in older patients with acute myeloid leukemia treated with
azacitidine or conventional care. Leukemia 1–12. https://doi.org/
10.1038/s41375-018-0257-z
17. Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A,
Abdelkarim M, Blagitko-Dorfs N, Döhner K, Bullinger L, Duyster
J, LübbertM, Hackanson B (2017) Evaluating the impact of genetic
and epigenetic aberrations on survival and response in acute mye-
loid leukemia patients receiving epigenetic therapy. Ann Hematol
96:559–565. https://doi.org/10.1007/s00277-016-2912-7
18. Nieto M, Samper E, Fraga MF, González de Buitrago G, Esteller
M, SerranoM (2004) The absence of p53 is critical for the induction
of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 23:735–743.
https://doi.org/10.1038/sj.onc.1207175
19. Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme
C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P (2014)
Prognostic value of TP53 gene mutations in myelodysplastic syn-
dromes and acute myeloid leukemia treated with azacitidine. Leuk
Res 38:751–755. https://doi.org/10.1016/j.leukres.2014.03.012
20. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes
JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju
N, Quintas-CardamaA, Ravandi F, KeatingM, Borthakur G (2014)
Prognostic implications of chromosome 17 abnormalities in the
context of monosomal karyotype in patients with acute myeloid
leukemia and complex cytogenetics. Clinical Lymphoma,
Myeloma and Leukemia 14:163–171. https://doi.org/10.1016/j.
clml.2013.07.009
21. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H,
Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R,
Malcovati L, Levine MF, Arango JE, Zhou Y, Sole F, Cargo CA,
Haase D, CreignouM, Germing U, Zhang Y, GundemG, Sarian A,
van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O,
Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I,
Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T,
Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett
JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo
L, Sanz G, Ades L, Della Porta MG, Smith AG,Werner Y, Patel M,
Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K,
Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M,
Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY,
Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N,
Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-
Lindberg E, Ogawa S, Papaemmanuil E (2019) Implications of
TP53 allelic state for genome stability, clinical presentation and
outcomes in myelodysplastic syndromes. bioRxiv. https://doi.org/
10.1101/2019.12.19.868844
22. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Laï JL,
Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R,
Kerckaert JP (1992) Mutations of the P53 gene in acute myeloid
leukaemia. Br J Haematol 80:178–183. https://doi.org/10.1111/j.
1365-2141.1992.tb08897.x
23. Haferlach C, Dicker F, Herholz H, Schnittger S, KernW, Haferlach
T (2008)Mutations of the TP53 gene in acute myeloid leukemia are
strongly associated with a complex aberrant karyotype. Leukemia
22:1539–1541. https://doi.org/10.1038/leu.2008.143
24. Seifert H, Mohr B, Thiede C, Oelschlägel U, Schäkel U, Illmer T,
Soucek S, Ehninger G, SchaichM (2009) The prognostic impact of
17p (p53) deletion in 2272 adults with acute myeloid leukemia.
Leukemia 23:656–663. https://doi.org/10.1038/leu.2008.375
25. Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H,
Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P,
Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T,
Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K,
Döhner H (2012) TP53 alterations in acute myeloid leukemia with
complex karyotype correlate with specific copy number alterations,
monosomal karyotype, and dismal outcome. Blood 119:2114–
2121. https://doi.org/10.1182/blood-2011-08-375758
26. Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD,
Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM,
LitzowMR, Luger SM, Paietta EM, Rowe JM, Vance GH,Wiernik
1559Ann Hematol (2020) 99:1551–1560
P, Wiktor AE, Zhang Y, Tallman MS, ECOG-ACRIN Cancer
Research Group (2017) Independent prognostic significance of
monosomy 17 and impact of karyotype complexity in monosomal
karyotype/complex karyotype acute myeloid leukemia: results
from four ECOG-ACRIN prospective therapeutic trials. Leuk Res
59:55–64. https://doi.org/10.1016/j.leukres.2017.05.010
27. Wierzbowska A, Wawrzyniak E, Pluta A, Robak T, Mazur GJ,
Dmoszynska A, Cermak J, Oriol A, Lysak D, Arthur C, Doyle M,
Xiu L, Ravandi F, Kantarjian HM (2018) Decitabine improves
response rate and prolongs progression-free survival in older pa-
tients with newly diagnosed acute myeloid leukemia and with
monosomal karyotype: a subgroup analysis of the DACO-016 trial.
Am J Hematol 93:E125–E127. https://doi.org/10.1002/ajh.25062
28. Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis
A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus
P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser
A, Aul C, de Witte T, Wijermans PW (2011) Low-dose decitabine
versus best supportive care in elderly patients with intermediate- or
high-risk myelodysplastic syndrome (MDS) ineligible for intensive
chemotherapy: final results of the randomized phase III study of the
European Organisation for Research and Treatment of Cancer
Leukemia Group and the German MDS Study Group. J Clin
Oncol 29:1987–1996. https://doi.org/10.1200/JCO.2010.30.9245
29. Soenen-Cornu V, Preudhomme C, Laï JL, Zandecki M (1999) del
(17p) in myeloid malignancies. Atlas Genet Cytogenet Oncol
Haematol 3(4):198-201. https://doi.org/10.4267/2042/37563
30. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A,
Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J,
Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D,
Minden M, Arthur C (2012) Multicenter, randomized, open-label,
phase III trial of decitabine versus patient choice, with physician
advice, of either supportive care or low-dose cytarabine for the
treatment of older patients with newly diagnosed acute myeloid
leukemia. J Clin Oncol 30:2670–2677. https://doi.org/10.1200/
JCO.2011.38.9429
31. Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A,
Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger
KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser
A, Aul C, de Witte T, Wijermans PW, Lübbert M (2015)
Decitabine versus best supportive care in older patients with refrac-
tory anemia with excess blasts in transformation (RAEBt) - results
of a subgroup analysis of the randomized phase III study 06011 of
the EORTC Leukemia Cooperative Group and German MDS
Study Group (GMDSSG). Ann Hematol 94:2003–2013. https://
doi.org/10.1007/s00277-015-2489-6
32. Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab
O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kambhampati S,
Parmar S, Nischal S, Hueck C, Suzuki M, Freidman E, Pellagatti A,
Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Mcmahon C, Gore
SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM,
Verma A (2011) Aberrant epigenetic and genetic marks are seen in
myelodysplastic leukocytes and reveal Dock4 as a candidate pathogen-
ic gene on chromosome 7q. J Biol Chem 286:25211–25223. https://
doi.org/10.1074/jbc.M111.235028
33. Blum S, Greve G, Lübbert M (2017) Innovative strategies for ad-
verse karyotype acute myeloid leukemia. Curr Opin Hematol 24:
89–98. https://doi.org/10.1097/MOH.0000000000000318
34. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker
PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T,
Hong W-J, Chyla B, Potluri J, Pollyea DA, Letai A (2019)
Venetoclax combined with decitabine or azacitidine in treatment-
naive, elderly patients with acute myeloid leukemia. Blood 133:7–
17. https://doi.org/10.1182/blood-2018-08-868752
35. Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt
M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U,
Kuendgen A, Götze KS, Lindemann HW,Müller-TidowC, Heil G,
Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A,
Krauter J, Brugger W, de Wit M, Wäsch R, Becker H, May AM,
Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H, on behalf
of the DECIDER Study Team (2020) Valproate and retinoic acid in
combination with decitabine in newly diagnosed elderly non-fit
acute myeloid leukemia patients: results of a multicenter, random-
ized 2x2 phase II trial. J Clin Oncol 38:257–270. https://doi.org/10.
1200/JCO.19.01053
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Affiliations
Heiko Becker1,2 & Dietmar Pfeifer1 & Gabriele Ihorst1,3 &Milena Pantic1 & Julius Wehrle1,2 & Björn H. Rüter1 &
Lars Bullinger4,5 & Björn Hackanson1,6 & Ulrich Germing7 & Andrea Kuendgen7 & Uwe Platzbecker8,9 &
Konstanze Döhner4 & Arnold Ganser10 & Anne Hagemeijer11 & Pierre W. Wijermans12 & Hartmut Döhner4 &
Justus Duyster1,2 &Michael Lübbert1,2
1 Department of Medicine I, Medical Center – University of Freiburg,
Faculty of Medicine, University of Freiburg, Hugstetter Straße 55,
79106 Freiburg, Germany
2 German Cancer Consortium (DKTK) partner site,
Freiburg, Germany
3 Clinical Trials Unit, Medical Center – University of Freiburg,
Faculty of Medicine, University of Freiburg, Freiburg, Germany
4 Department of Internal Medicine III, University Hospital of Ulm,
Ulm, Germany
5 Charité University Medicine, Berlin, Germany
6 Interdisciplinary Cancer Center Augsburg, Augsburg, Germany
7 Dept. of Hematology, Oncology and Clincal Immunology,
University Clinic Düsseldorf, Heinrich-HeineUniversity Düsseldorf,
Düsseldorf, Germany
8 University Hospital Dresden, Dresden, Germany
9 University Hospital Leipzig, Leipzig, Germany
10 Department of Hematology, Hemostasis, Oncology and Stem Cell
Transplantation, Hannover Medical School, Hannover, Germany
11 Department of Human Genetics, University of Leuven,
Leuven, Belgium
12 Haga Ziekenhuis, The Hague, The Netherlands
1560 Ann Hematol (2020) 99:1551–1560
